Shares of Immunic, Inc. (NASDAQ:IMUX – Get Free Report) have received an average rating of “Buy” from the twelve analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and three have issued a strong buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $47.25.
IMUX has been the topic of a number of recent analyst reports. B. Riley Financial cut their price objective on Immunic from $40.00 to $27.00 and set a “buy” rating on the stock in a research note on Friday, May 22nd. HC Wainwright restated a “buy” rating and set a $22.00 price target (up from $5.00) on shares of Immunic in a report on Thursday, April 30th. Wedbush started coverage on shares of Immunic in a research report on Monday. They issued an “outperform” rating and a $45.00 price target on the stock. Wolfe Research assumed coverage on shares of Immunic in a research note on Friday, May 22nd. They issued an “outperform” rating on the stock. Finally, Roth Capital reiterated a “buy” rating and set a $19.00 price objective on shares of Immunic in a research report on Thursday, May 14th.
Check Out Our Latest Research Report on Immunic
Immunic Stock Down 2.7%
Immunic (NASDAQ:IMUX – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.36. As a group, equities research analysts expect that Immunic will post -3.88 EPS for the current year.
Institutional Trading of Immunic
Large investors have recently bought and sold shares of the business. Avidity Partners Management LP raised its position in shares of Immunic by 42.6% in the 1st quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock worth $7,436,000 after acquiring an additional 2,000,000 shares in the last quarter. CTC Alternative Strategies Ltd. acquired a new position in shares of Immunic in the 1st quarter valued at about $27,000. Bank of America Corp DE boosted its position in shares of Immunic by 80,724.2% during the 1st quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock valued at $160,000 after purchasing an additional 143,689 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Immunic during the 1st quarter valued at about $33,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Immunic during the first quarter worth approximately $187,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.
About Immunic
Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.
Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.
See Also
- Five stocks we like better than Immunic
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.
